Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Variability in conflict of interest disclosures by physicians presenting trauma research.

Wong K, Yi PH, Mohan R, Choo KJ.

World J Orthop. 2017 Apr 18;8(4):329-335. doi: 10.5312/wjo.v8.i4.329. eCollection 2017 Apr 18.

2.

Benchmarks for ethically credible partnerships between industry and academic health centers: beyond disclosure of financial conflicts of interest.

Meslin EM, Rager JB, Schwartz PH, Quaid KA, Gaffney MM, Duke J, Tierney WH.

Clin Transl Med. 2015 Dec;4(1):36. doi: 10.1186/s40169-015-0077-y. Epub 2015 Dec 14. Erratum in: Clin Transl Med. 2016 Dec;5(1):4.

3.

Appraisal tools for clinical practice guidelines: a systematic review.

Siering U, Eikermann M, Hausner E, Hoffmann-Eßer W, Neugebauer EA.

PLoS One. 2013 Dec 9;8(12):e82915. doi: 10.1371/journal.pone.0082915. eCollection 2013. Review.

4.

Developing clinical practice guidelines: target audiences, identifying topics for guidelines, guideline group composition and functioning and conflicts of interest.

Eccles MP, Grimshaw JM, Shekelle P, Schünemann HJ, Woolf S.

Implement Sci. 2012 Jul 4;7:60. doi: 10.1186/1748-5908-7-60.

5.

Concerned Journals, Editors And ICMJE.

[No authors listed]

Mens Sana Monogr. 2007 Jan;5(1):90-107. doi: 10.4103/0973-1229.32152. No abstract available.

6.

"Members of the same club": challenges and decisions faced by US IRBs in identifying and managing conflicts of interest.

Klitzman R.

PLoS One. 2011;6(7):e22796. doi: 10.1371/journal.pone.0022796. Epub 2011 Jul 29.

7.

Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials.

Rose SL, Krzyzanowska MK, Joffe S.

J Clin Oncol. 2010 Mar 10;28(8):1316-21. doi: 10.1200/JCO.2008.21.6606. Epub 2010 Jan 11.

8.

Prevalence of industry support and its relationship to research integrity.

Tereskerz PM, Hamric AB, Guterbock TM, Moreno JD.

Account Res. 2009 Apr-Jun;16(2):78-105. doi: 10.1080/08989620902854945.

9.

Criteria for evaluating tobacco control research funding programs and their application to models that include financial support from the tobacco industry.

Cohen JE, Zeller M, Eissenberg T, Parascandola M, O'Keefe R, Planinac L, Leischow S.

Tob Control. 2009 Jun;18(3):228-34. doi: 10.1136/tc.2008.027623. Epub 2009 Feb 24. No abstract available.

10.

Barriers to physician adherence to nonsteroidal anti-inflammatory drug guidelines: a qualitative study.

Cavazos JM, Naik AD, Woofter A, Abraham NS.

Aliment Pharmacol Ther. 2008 Sep 15;28(6):789-98.

11.

The changing face of surgical education: simulation as the new paradigm.

Scott DJ, Cendan JC, Pugh CM, Minter RM, Dunnington GL, Kozar RA.

J Surg Res. 2008 Jun 15;147(2):189-93. doi: 10.1016/j.jss.2008.02.014. Epub 2008 Mar 13.

12.

Soft targets: nurses and the pharmaceutical industry.

Jutel A, Menkes DB.

PLoS Med. 2008 Feb;5(2):e5. doi: 10.1371/journal.pmed.0050005. Review. No abstract available.

13.

Reporting science and conflicts of interest in the lay press.

Cook DM, Boyd EA, Grossmann C, Bero LA.

PLoS One. 2007 Dec 5;2(12):e1266.

14.

Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study.

Yank V, Rennie D, Bero LA.

BMJ. 2007 Dec 8;335(7631):1202-5. Epub 2007 Nov 16. Review.

15.
16.
17.
18.

Origin and funding of the most frequently cited papers in medicine: database analysis.

Patsopoulos NA, Ioannidis JP, Analatos AA.

BMJ. 2006 May 6;332(7549):1061-4. Epub 2006 Mar 17.

19.

Tobacco industry manipulation of research.

Bero LA.

Public Health Rep. 2005 Mar-Apr;120(2):200-8. Review. No abstract available.

20.

Relationship between conflicts of interest and research results.

Friedman LS, Richter ED.

J Gen Intern Med. 2004 Jan;19(1):51-6.

Supplemental Content

Support Center